Disc Medicine recently released its latest 10-Q report. Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases in the United States. Its pipeline includes bitopertin, DISC-0974, DISC-3405, and the preclinical program DISC-0998, with work centered on red blood cell biology, heme biosynthesis, and iron homeostasis.
In Item 2, Management’s Discussion and Analysis, the company said it had $730.2 million in cash, cash equivalents and marketable securities as of March 31, 2026. Disc Medicine said that balance is expected to fund current operating and capital expenditure plans, plus debt service obligations, into 2029, without assuming any future cash from product sales or partnerships.
The company said it has not generated revenue since inception and does not expect product revenue in the near future, if at all. Research and development remains the main expense category, and management said those costs are expected to rise substantially as programs move further through clinical development.
Bitopertin remains the lead program in the heme biosynthesis portfolio. Disc Medicine said it completed enrollment in APOLLO, its Phase 3 trial in erythropoietic protoporphyria and X-linked protoporphyria, with 183 patients in the study, and expects topline data in the fourth quarter of 2026. The company also said the FDA issued a complete response letter in February 2026 after accepting the NDA for review in November 2025; the agency said AURORA and BEACON showed that bitopertin lowered whole blood metal-free PPIX, but did not establish that changes in PPIX tracked with sunlight exposure-based endpoints.
Disc Medicine said it plans a Type A meeting with the FDA in the second quarter of 2026 to discuss resubmission. If APOLLO data support the application, the company said it would submit a response to the CRL and would then expect an FDA decision by mid-2027.
On the iron homeostasis side, DISC-0974 is being developed for anemia of myelofibrosis and anemia of inflammatory bowel disease. Disc Medicine said initial data from the Phase 2 RALLY-MF study, reported in December 2025, showed meaningful anemia responses across patient subgroups, including patients regardless of baseline transfusion status and regardless of concomitant JAK inhibitor use. Updated data are expected in June 2026, with topline data in the fourth quarter of 2026.
DISC-3405 is being studied in polycythemia vera and sickle cell disease. The company said it initiated RESTORE-PV in the first half of 2025 and a Phase 1b sickle cell study in October 2025, with initial data for both expected in the fourth quarter of 2026. Disc Medicine also said DISC-0998 remains in preclinical development for anemia associated with inflammatory diseases. The market has reacted to these announcements by moving the company's shares 0.08% to a price of $67.695. For the full picture, make sure to review Disc Medicine's 10-Q report.
